SOURCE: HealthSonix, Inc.

April 25, 2007 15:01 ET

HealthSonix Selects a Florida Studio for the Production of enSonix@home Infomercial

IRVINE, CA -- (MARKET WIRE) -- April 25, 2007 -- HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) announced today that it has selected MG Studios of Orlando, Florida to produce a series of HD infomercials to be launched this summer in Southeast Florida and one other test market to be selected. Following the successful completion of the test markets, the infomercials will be rolled out nationally in the fall of 2007.

"This is a tremendous opportunity for our studio," said Michael Gibilisco, President of MG Studios. "We are very impressed with the HealthSonix medical device, mainly because of its price point, documented success rates and the potential appeal to 70 million arthritis sufferers in North America alone."

John C May, Executive Producer of the Infomercial, remarks, "There are cardinal rules for producing a successful infomercial. Nearly all products do not meet the criterion; to find one that does is really special. The first rule is the most important. For an infomercial to be successful, there must be a need for the product in every household. And pain is definitely a factor in every home in the world. Pain is also a great motivator to cause purchase of the product. To top it off, the enSonix@home device is FDA approved. This is a point that we shall prominently promote to our television audience, thereby ensuring the consumer confidence required to gain a sale. Our customers can be certain that they are getting a great product with actual science behind it. We therefore have the potential to reach our goal, which is to have an enSonix@home in every home in the United States, to conveniently self treat a persons pain, in the comfort of their home."

"Not everyone in the world can attend one of our treatment facilities, hence the product that can be used at home," stated Dr. David Venturi, Medical Director of HealthSonix. "enSonix@home is a medical device that generates therapeutic sound pulses to reduce pain and relax muscles. It is particularly effective in treating the pain of arthritis, fibromyalgia, low back pain, and soft tissue injuries," added Dr. Venturi.

The enSonix@home personal use device has been registered and cleared with the United States, Food and Drug Administration (FDA), and has been designated as a class one device, the safest classification for medical devices with the FDA.


MG studios is a fully digital production and multimedia company in Orlando, FL. We specialize in film, video and post production under one roof located in our 6,000-square-foot facility, which includes a green screen, edit suites, animation suites and a recording studio. combining leading edge technology and experienced professional writers, directors, editors, animators and composers. MG Studios can creatively meet the high demands of any project.

About HealthSonix, Inc.

HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company. The Company's core offerings are based on proprietary, patent pending medical technologies that use sound pressure waves to administer sub-sensory micro vibration to the human body. Precisely formatted low frequency sound pulses are 80% effective in treating the pain of many diseases, particularly arthritis. All treatments and products are safe, non-invasive and have no known side effects.

Note: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.

Contact Information